Who Is at the Controls of 340B?

Tony Hagen @oncobiz | January 29, 2017
blood cells The 340B Drug Pricing Program, designed to provide support for outpatient drug purchases, severely lacks federal oversight, said BRG Healthcare, the business advisory group, in a report sponsored by the Alliance for Integrity and Reform of 340B (AIR340B). BRG increased its growth estimates for 340B and said the program would exceed $23 billion in total sales by 2021 (Figure 1). That amount is higher than the total Medicare Part B drug reimbursement in 2014, and the comparison is significant, BRG said, because Medicare Part B currently has significantly more administrative assistance from the Health Resources & Service Administration (HRSA) than 340B receives.

AIR340B is a coalition of patient advocacy groups, clinical care providers, and pharmaceutical companies that contend the 340B program has been stretched far beyond its original mandate to provide discounted drugs for uninsured indigent patients. The group includes the Community Oncology Alliance, which has stated that promoting 340B reform is among its goals for 2017. Drug industry observers have also said political inclination in Washington, DC, to change 340B is weak. One of the groups strongly in support of 340B is the 340B Coalition, which contends that 340B is an important safety net for patients that provides participating hospitals with an important source of funding for charity programs.

340B allows qualifying providers to obtain drugs from manufacturers at deep discounts. It is not necessary for those providers to lower what they charge for that medicine, and the margins on sales make it easier for hospitals and other institutions to provide comprehensive care for those who need it. Critics allege that those 340B savings are being pocketed or misused by unscrupulous providers and that providers who do not qualify for 340B participation are placed at a competitive disadvantage. The potential for financial gain and the lack of regulatory control are seen as major reasons for the extraordinary growth of the program.



BRG said 340B is overseen by an agency that has just 22 part-time auditors who, by 2021, will each be responsible for watching over 4000 entities and more than $1 billion in 340B drug sales. “The 340B program is currently administered by HRSA’s Office of Pharmacy Affairs, which operates on an annual budget of approximately $10 million. This pales in comparison to the $733 million in federal administrative budget for Medicare and Medicaid and highlights the challenges HRSA faces in effectively regulating the 340B program,” BRG said. Compliance issues—for example, drug discounts being applied in cases where charitable assistance is not necessary—have been identified as rife by government investigations.

The 340B program requires drug manufacturers to provide discounts as deep as 50% on drugs prescribed by participating providers. However, the program is criticized because, in many cases, these discounts are not passed along to patients. Providers sometimes do not apply the difference between the discount and the regular drug price toward charitable care. Critics say the program’s enormous profit potential has contributed to huge expansion of hospital networks. Since the beginning of 2015, over 390 hospitals have enrolled in the program for the first time, BRG said.

The 340B program is also blamed for acquisitions by hospitals of private practices and exacerbation of business difficulties for independent practices that do not have access to the program.

BRG said that “340B hospitals have grown from accounting for 13% of Medicare Part B drug reimbursement in 2010 to 25% by 2015. Part of this growth is attributable to new hospital enrollments, but over half of the growth is due to expanded drug utilization at existing 340B hospitals. The result is a shift in site of care to the higher-cost outpatient setting that is driven, at least in part, by the sizeable margins realized by hospitals on drugs purchased through the 340B program.” For example, Part B drug payments to hospitals that were enrolled in 340B prior to 2010 totalled $1.8 billion in 2010 and $3.9 billion in 2015, the report said. Meanwhile, among hospitals that enrolled in 340B in 2010 or later, Medicare Part B payments rose from $0.1 billion in 2010 to $1.9 billion in 2015.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Redefining Treatment Paradigms in the Management of Chronic Lymphocytic LeukemiaOct 05, 20172.0
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Publication Bottom Border
Border Publication